

The expression level and prognostic value of HIPK3 among non-small-cell lung cancer patients in China

Yifei Liu^{1,*}
 Li Qian^{1,*}
 Juanjuan Yang¹
 Hua Huang¹
 Jia Feng¹
 Xiaoli Li¹
 Tingting Bian¹
 Honggang Ke²
 Jian Liu³
 Jianguo Zhang¹

¹Department of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China; ²Department of Thoracic Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China; ³Department of Chemotherapy, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China

*These authors contributed equally to this work

Correspondence: Jian Liu
 Department of Chemotherapy, Affiliated Hospital of Nantong University, 20 Xisi Road, Nantong, Jiangsu, China
 Email niuniu68915@sina.com

Jianguo Zhang
 Department of Pathology, Affiliated Hospital of Nantong University, 20 Xisi Road, Nantong, Jiangsu, China
 Email jgz_edu@163.com

Background: Lung cancer is one of the most common malignancies in the world and is at the forefront of causes of all cancer deaths. Identification of new prognostic predictors or therapeutic targets might improve a patient's survival rate.

Purpose: The Homeodomain interacting protein kinases (HIPKs) function as modulators of cellular stress responses and regulate cell differentiation, proliferation and apoptosis, but the function of HIPK3 is remain unknown.

Patients and methods: We used quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting methods to detect the expression of HIPK3. A total of 206 samples were obtained from patients and Immunochemical evaluation to determine HIPK3 protein expression. HIPK3 protein levels in non-small cell lung cancer (NSCLC) were correlated with the clinical characteristics of patients and their 5-year survival rate. In addition, HIPK3 knockdown by specific RNAi promoted cell proliferation, migration, and invasion in A549 and HCC827 cancer cell lines.

Results: The quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting methods to demonstrate that HIPK3 expression was significantly down-regulated in non-small cell lung cancer (NSCLC) tissues compared with that in normal lung tissues. At the same time, the results of immunohistochemistry assays showed that low expression of HIPK3 was significantly associated with pathology grade; tumor, node, and metastases (TNM) stage; lymph node metastasis; Ki-67 expression; and the 5-year survival rate in NSCLC patients. Univariate analysis revealed that HIPK3 expression, Ki-67 expression, tumor diameter, TNM stage, and age were significantly associated with a poor prognosis. The multivariable analysis illustrated that HIPK3, tumor diameter, TNM, Ki-67 expression, and age had effects on the overall survival of NSCLC patients independently. Kaplan-Meier survival curves revealed that NSCLC patients with a lower HIPK3 expression had a poorer prognosis. In addition, *in vivo* results also confirmed that HIPK3 over-expression could inhibit tumor growth.

Conclusion: Our findings confirmed that low expression of HIPK3 in NSCLC tissues was significantly correlated with poor survival rates after curative resection. HIPK3 could potentially be used as a valuable biomarker in the prognosis of the survival of NSCLC patients.

Keywords: HIPK3, non-small-cell lung cancer, immunohistochemistry, tumor suppressor gene, prognosis, biomarker

Plain language summary

The expression of HIPK3 mRNA and protein level was significantly downregulated in human non-small-cell lung cancer (NSCLC). Low expression of HIPK3 was significantly associated with pathology grade, TNM stage, lymph node metastasis, Ki-67 expression, and 5-year survival rate in NSCLC patients. HIPK3 silencing promoted invasion and metastasis in NSCLC. HIPK3 could be potentially used as a valuable biomarker for predicting the prognosis of NSCLC patients.

Introduction

According to the statistical analysis released by the American Cancer Society, in 2018, there were ~234,030 newly diagnosed patients with lung cancer, accounting for 13.5% of all newly diagnosed malignancies. In addition, ~154,050 people died from lung cancer each year, accounting for 25.3% of all cancer-related deaths.¹ China has not escaped this worldwide trend, and the data being gathered in the country on the cause of death have ranked lung cancer as the first among all malignant tumor deaths for 7 consecutive years. For example, in Beijing, the number of deaths due to lung cancer nearly tripled between 1974 and 2003.

In general, lung cancer cells are classified into two types – non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC).² NSCLC accounts for 80%–85% of all lung cancers.³ The treatment for lung cancer is mainly surgery in combination with chemotherapy, radiotherapy, immunotherapy, and so on. Despite the advances in cancer treatments, the 5-year survival rate for lung cancer remains <18%^{4,5} mainly due to the failure of early detection and diagnosis of the disease. In ~85% of patients, the primary lesion will metastasize and invade lymph nodes or other organs at the late stage; at this stage, the treatment is not effective and the prognosis is poor. Therefore, early diagnosis and a comprehensive treatment to prevent and control NSCLC metastasis are critical to reduce mortality.

FAS/HIPK, a member of the *HIPK* family of genes, was discovered in 1998 by Kim et al⁶ through the double hybridization of yeast and by obtaining the main cDNA clone of this family member. The family comprises *HIPK1*, *HIPK2*, *HIPK3*, and *HIPK4*, of which, we focus on *HIPK3* in this study.

There have been few studies on *HIPK3*, especially on its association with lung cancer. In this study, we confirmed a lower expression of *HIPK3* in NSCLC tissues than in normal lung tissues and demonstrated that *HIPK3* played a role in the proliferation, migration, and invasion of these cancer cells. Our findings suggested that *HIPK3* had potential clinical applications as a prognostic predictor or therapeutic target in NSCLC.

Materials and methods

Patients and tissue samples

A total of 206 samples were obtained from patients who had undergone lung resection without immunotherapy or radiation therapy at the Thoracic Surgery Department of the Affiliated Hospital of Nantong University (Nantong, China) between May 2008 and July 2010. Quantitative real-time qRT-PCR was used to investigate 30 patients who underwent curative resection between January 2015 and August

2016 at the same hospital. Follow-up of all patients was completed by May 2017. The tissues that were previously pathologically determined to be NSCLC and matching non-cancerous tissues were obtained from each patient. The procedure was approved by the research ethics committee of the Affiliated Hospital of Nantong University (Nantong, China), and the written informed consent was obtained from each patient.

qRT-PCR analysis

For qRT-PCR analysis, total RNA was isolated from NSCLC samples using TRIzol (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's protocol. Reverse transcription and PCR were performed using a High Capacity cDNA Reverse Transcription Kit and QuantiTect SYBR Green PCR Kit (Thermo Fisher Scientific). The primer sequences for the genes were defined as follows:

HIPK3: forward 5'-ACATTGGAAGAGCATGAGG CAGAGA-3'; reverse 5'-CTGCTGAAAAGCATCAC CACAACCA-3'

GAPDH: forward 5'-GCAGGGGGGAGCCAAAA GGGT-3'; reverse 5'-TGGGTGGCAGTGATGGCA TGG-3'.

Immunohistochemical (IHC) evaluation

For statistical analyses, the number of cells showing SYBR green staining on the nuclei and cytoplasm in 10 representative microscopic fields were counted, and the percentage of positive cells was calculated. A semiquantitative assessment of the IHC reactions for *HIPK3* was used to score staining results as follows: 0 (negative, ≤5% of cells), 1+ (low, 6%–25%), 2+ (intermediate, 26%–50%), and 3+ (high, ≥51%). The count was recorded as the percentage of positive cells. In one-half of the samples, staining was repeated three times to avoid potential technical errors. The evaluation procedures were independently performed by three experienced pathologists using a multi-head microscope (Precise Instrument Co., Ltd., Beijing, China) to reach a consensus.

In addition to the aforementioned method, another quantitative evaluation method was used. *HIPK3* sections were scanned by NanoZoomer slide scanners (NanoZoomer-XR C12000; Hamamatsu, Japan) and observed with NDP.view software (NDP.view2 U12388-01; Hamamatsu). The tumor area was determined as a 20× field (545×577 μm²) viewed by NDP.view in the center. The number of *HIPK3* cells was counted in four hotspots (20×) using a computer-automated method (Imagepro plus 6.0; Media Cybernetics Inc., Bethesda, MD, USA), and then mean densities were

calculated. The cutoff value of the HIPK3 cell counts was determined by the 5-year survival-specific receiver operating characteristic curve analysis according to the Youden's index. Then, a low HIPK3 cell count was not more than the cutoff value and a high HIPK3 cell count was greater than the cutoff value.

Cell culture and transfection

A549 and HCC827 cells were purchased from the American Type Culture Collection (Manassas, VA, USA) and cultured in Dulbecco's Modified Eagle's Medium supplemented with 10% FBS. Cells were transfected with *HIPK3* siRNA (Genepharma, Suzhou, China) and their corresponding negative control (siRNA ctrl) at a final concentration of 50 nmol/L using Lipofectamine 2000 Transfection Reagent (Thermo Fisher Scientific) according to the manufacturer's instructions.

Cell invasion and cell migration

Transwell membranes (8 μ m pore size) on 24-well plates were coated with Matrigel (BD Biosciences, San Jose, CA, USA) and used for cell invasion assays. Equal numbers (1×10^5) of nontransfected cells and cells transfected with siRNA-targeting *HIPK3* (siR-*HIPK3*) or *HIPK3* vector were plated in separate wells. The cells were cultured overnight in a serum-free medium before being trypsinized and resuspended at a density of 2×10^5 cells/mL in a medium containing 2% FBS. The cells were then added to the upper chamber of the incubator with medium containing 20% FBS as the chemoattractant in the lower chamber. Medium containing 2% FBS was added to the lower chamber and used as the control. Matrigel and the cells remaining in the upper chamber were removed using cotton swabs following incubation for 24 hours. The cells on the lower surface of the membrane were fixed with formaldehyde solution and stained with staining solution. The cells in at least five random microscopic fields ($\times 200$) were counted and photographed. For the migration assay, the transfected cells were plated and incubated until the formation of 80%–90% confluent monolayer. AP-20 micropipette tips were then used to mimic a scratch wound. The ratio of migratory capacity was determined by measuring the width of the scratch at 0 and 24 hours using bright-field microscopy.

Tumor xenograft model in nude mice

The nude mouse xenograft model was developed, which was xenografted with a human lung cancer cell line, NSCLC A549 cell. This mice model was obtained from Shanghai Animal Experimental Center. Mice were randomly divided into four groups, with four mice in each group, namely the

pcDNA3.1 control group (group A), normal saline control group (group B), *HIPK3*-shRNA group (group C), and *HIPK3* overexpression group (group D). All supplied mice were female and weighed 19–20 g. All treatments were administered for 4 weeks.

Western blot analysis

For Western blotting, 50 μ g protein was separated by SDS-PAGE and transferred onto polyvinylidene difluoride (PVDF) membranes. The membranes were blocked with 5% nonfat milk for 1 hour and incubated overnight at 4°C with their corresponding primary antibodies (1:1,000 dilution in 5% nonfat milk), followed by incubation with secondary antibodies conjugated with horseradish peroxidase (HRP; 1:8,000 dilution in 5% nonfat milk) for 2 hours at room temperature. The membranes were then detected using an electrogenerated chemiluminescence kit (Thermo Fisher Scientific).

Statistical analyses

All computations were performed using SPSS, Version 24.0 (IBM Corporation, Armonk, NY, USA). All values were expressed as the mean \pm standard error. *HIPK3* expression and clinicopathological features were analyzed using Pearson's chi-squared test. Univariate and multivariate analyses were performed using the Cox regression model to test independent prognostic factors, and 95% CI was recorded for each marker. Kaplan–Meier analysis and the log-rank test were used to analyze the survival rate. A *P*-value < 0.05 was considered statistically significant.

Results

Decreased *HIPK3* expression in NSCLC tissues

The protein and mRNA levels of *HIPK3* expression were quantified using Western blotting and qRT-PCR, respectively, in NSCLC tissues and normal tissues. As illustrated in Figure 1, both Western blotting and qRT-PCR showed a visible decrease in *HIPK3* expression levels in NSCLC tissues compared with that in normal tissues.

Decreased *HIPK3* expression in NSCLC tissues was associated with poor clinicopathological characteristics

IHC was performed in 206 NSCLC tissue samples to investigate the *HIPK3* protein expression profile. The cytoplasm and nucleus of the carcinoma cells showed positive immunostaining (Figure 2). Table 1 shows the relationship between the expression of *HIPK3* and the clinicopathological characteristics of




Figure 1 HIPK3 expression decreased in NSCLC tissues.

Notes: (A and B) Levels of HIPK3 in normal lung tissues and tumor tissues were measured by Western blotting. Values are represented as mean±SD. ** $P < 0.01$. (C) Quantitative real-time PCR (qRT-PCR) assays showed that HIPK3 expression was lower in NSCLC tissues than in normal lung tissues.

Abbreviations: NSCLC, non-small-cell lung cancer; qRT-PCR, quantitative real-time PCR.

the tissue samples from 206 NSCLC patients. We identified that HIPK3 protein expression was significantly associated with pathology grade ($P=0.004$), TNM stage ($P=0.002$), lymph node metastasis ($P=0.010$), Ki-67 expression ($P=0.015$), and 5-year survival rate in NSCLC patients ($P=0.001$). However, there was no correlation between HIPK3 protein expression and other prognostic factors such as age, sex, tumor diameter, smoking status, and histological type.

Decreased HIPK3 protein expression in NSCLC predicted poor survival

Univariate and multivariate analyses were used with the Cox proportional hazards model to identify related prognostic factors for overall survival. The univariate analysis revealed that the following variables were significantly associated with a poor prognosis: *HIPK3* expression ($P=0.001$), Ki-67 expression ($P=0.027$), tumor size ($P < 0.001$), TNM stage ($P < 0.001$), and age ($P=0.029$). To verify the accuracy of the results, multivariate analysis was performed using the significant ($P < 0.05$) variables from the univariate analysis. The multivariate analysis revealed that the *HIPK3* ($P < 0.001$), tumor size ($P < 0.001$), TNM stage ($P < 0.001$), Ki-67 expression ($P=0.027$), and age ($P=0.006$) had independent prognostic value on the overall survival of NSCLC patients (Table 2). Kaplan–Meier survival curves revealed that a

poorer prognosis was found in NSCLC patients with lower *HIPK3* expression levels (Figure 3).

HIPK3 participated in multiple biological processes in NSCLC cells

To further verify the expression of *HIPK3* in NSCLC cells in vitro, *siR-HIPK3* for knocking down *HIPK3* mRNA was synthesized. Western blot analysis showed that *siR-HIPK3* reduced *HIPK3* protein levels in A549 as shown in Figure 4A and B. As indicated by the results, *siR-HIPK3* promoted the migratory ability and invasive capability of the NSCLC cell line. *siR-HIPK3* further confirmed the result by enhancing the migratory ability and the invasive capability of both cell lines (Figure 4C and D). To further verify the results, we repeated the experiments in another lung cancer cell line, HCC827. The aforementioned results were confirmed again in HCC827 (Figure 5). Taken together, the results showed that *HIPK3* was negatively expressed in the progression and metastasis of NSCLC.

HIPK3 inhibited the proliferation of NSCLC cells in vivo

We further studied the effect of HIPK3 on tumor volume in vivo, and the results showed that the overexpression of HIPK3 inhibited tumor growth and the overexpression of HIPK3-shRNA promoted tumor growth (Figure 6A and B).




Figure 2 Representative images of IHC staining of HIPK3 expression in NSCLC tissue samples and benign tumors.

Notes: (A1–B3) Strong staining of HIPK3 in NSCLC tissues; (C1–D3) light staining of HIPK3 in NSCLC tissues; (E1–F3) negative staining of HIPK3 in NSCLC tissues; (F1–F3) positive staining of HIPK3 in surrounding normal tissues. (A1–F1) Original magnification, $\times 40$; (A2–F2) original magnification, $\times 200$; (A3–F3) original magnification, $\times 400$.

Abbreviations: IHC, immunohistochemical; NSCLC, non-small-cell lung cancer.

Discussion

The function of HIPKs is to modulate cellular stress responses and regulate cell differentiation, proliferation, and apoptosis.⁷ The *HIPK* family genes comprises *HIPK1*, *HIPK2*, and *HIPK3*, which share similar domain-frustrated structures on serine and threonine residues. Some studies have found that the expression of *HIPKs* was located mainly in the nucleus and enhanced the inhibitory activity of the natural killer (NK) protein family.⁸ Studies by Kim et al⁶ found that HIPKs were involved in a variety of cellular processes and played a role by mediating the phosphorylation of several important protein molecules. They represented

a family of highly conserved kinases and were involved in cellular processes including regulation of cell death, proliferation, and differentiation. In addition, it has been reported that these kinases are involved in the regulation of cellular responses to DNA damage.⁷ The HIPK family not only regulates other proteins in the nucleus, but also regulates those in the cytoplasm and cell membrane and can participate in biological processes, such as cell proliferation, differentiation, and apoptosis, by affecting the phosphorylation of corresponding proteins. The site and mode of action depend on the conditions that the protein encounters after it has been removed from the nucleus.^{9,10}

Table 1 Correlation of HIPK3 expression with clinicopathological characteristics of NSCLC patients

Clinicopathological characteristics	n	Low expression, n (%)	High expression, n (%)	Chi-squared	P-value
Total	206				
Gender				4.072	0.052
Male	135	88 (65.2)	47 (34.8)		
Female	71	36 (50.7)	35 (49.3)		
Age (years)				0.569	0.462
<60	74	42 (56.8)	32 (43.2)		
≥60	132	82 (62.1)	50 (37.9)		
Tumor diameter (cm)				2.968	0.096
<3	139	78 (56.1)	61 (43.9)		
≥3	67	46 (68.7)	21 (31.3)		
Smoking status				0.651	0.573
Never	192	117 (60.9)	75 (39.1)		
Ever	14	7 (50.0)	7 (50.0)		
Pathology grade				11.279	0.004 ^a
Well	35	16 (45.7)	19 (54.3)		
Moderate	74	38 (51.4)	36 (48.6)		
Poor	97	70 (72.2)	27 (27.8)		
Histological type				1.308	0.520
Adenocarcinoma	131	75 (57.3)	56 (42.7)		
Squamous cell carcinoma	66	43 (65.2)	23 (34.8)		
Adenosquamous carcinoma	9	6 (66.7)	3 (33.3)		
TNM stage				15.246	0.002 ^a
I	45	18 (40.0)	27 (60.0)		
II	47	25 (53.2)	22 (46.8)		
III	71	53 (74.6)	18 (25.4)		
IV	43	28 (65.1)	15 (34.9)		
Lymph node metastasis				6.856	0.010 ^a
Absent	100	51 (51.0)	49 (49.0)		
Present	106	73 (68.9)	33 (31.1)		
Ki67 expression				6.624	0.015 ^a
Low	69	33 (47.8)	36 (52.2)		
High	137	91 (66.4)	46 (33.6)		
5-year survival				11.737	0.001 ^a
No	150	101 (67.3)	49 (32.7)		
Yes	56	23 (41.1)	33 (58.9)		

Note: ^aP<0.05.

Abbreviation: NSCLC, non-small-cell lung cancer.

HIPK1 protein is involved in the biological processes of cell proliferation, activation, and apoptosis by regulating the phosphorylation of many proteins and activation of some signaling pathways.^{11,12} Other studies have found that HIPK1 protein plays a role in promoting apoptosis to reduce tumor progression. These findings also showed that this protein depends on partner proteins to function. For example, under certain conditions, HIPK1 phosphorylates its partner protein Daxx to redistribute within the cytoplasm by influencing

localization and transcriptional repression activities in Daxx cells.^{13,14} Studies have shown that *HIPK1* plays an important role in oncogenesis and that the incidence or size of tumor formation in *HIPK1* knockout mice is significantly reduced. This suggests a phenomenon associated with DNA damage-induced apoptosis. These data also suggest that *HIPK1* is involved, to some extent, in a reaction to repair the damaged DNA, a process that might be initiated through its interaction with p53.¹⁴

Table 2 Univariate and multivariate analyses of prognostic factors in NSCLC patients for 5-year survival

Variable	Univariate analysis		Multivariate analysis	
	P> z	HR (95% CI)	P> z	HR (95% CI)
HIPK3 expression				
Low (n=124) vs high (n=82)	0.001 ^a	1.883 (1.299–2.729)	<0.001 ^a	2.007 (1.400–2.877)
Gender				
Male (n=135) vs female (n=71)	0.081	0.718 (0.495–1.042)	–	–
Age (years)				
<60 (n=74) vs ≥60 (n=132)	0.029 ^a	1.498 (1.042–2.153)	0.006 ^a	1.648 (1.157–2.347)
Tumor diameter (cm)				
<3 (n=139) vs ≥3 (n=67)	<0.001 ^a	0.368 (0.238–0.570)	<0.001 ^a	0.368 (0.246–0.549)
Smoking status				
Never (n=192) vs ever (n=14)	0.430	0.752 (0.371–1.526)	–	–
Pathology grade				
Well+moderate (n=109) vs poor (n=97)	0.636	0.912 (0.624–1.333)	–	–
Histological type				
Adenocarcinoma (n=131) vs squamous cell carcinoma (n=66) vs adenosquamous carcinoma (n=9)	0.981	1.004 (0.734–1.374)	–	–
Lymph node metastasis				
Absent (n=100) vs present (n=106)	0.223	1.408 (0.812–2.441)	–	–
TNM stage				
I+II (n=92) vs III+IV (n=114)	<0.001 ^a	3.149 (1.868–5.309)	<0.001 ^a	3.600 (2.445–5.300)
Ki67 expression				
Low (n=69) vs high (n=137)	0.027 ^a	0.584 (0.363–0.940)	0.027 ^a	0.641 (0.433–0.950)

Note: ^aP<0.05.

Abbreviation: NSCLC, non-small-cell lung cancer.

As a tumor suppressor gene, *HIPK2* is involved in the suppression of the occurrence and metastasis of several tumors. Nodale et al¹⁵ found that *HIPK2* inhibited the spread of human breast cancer cells by down-regulating vimentin.




Figure 3 Kaplan–Meier analysis revealed that the survival of NSCLC patients with high HIPK3 expression was significantly greater than the survival of NSCLC patients with low HIPK3 expression.

Abbreviation: NSCLC, non-small-cell lung cancer.

Similarly, D’Orazi et al¹⁶ used RNA interference (RNAi) to study the role of *HIPK2* in prostaglandin biosynthesis and found that *HIPK2* was inhibited by cytosolic phospholipase A2 (cPLA2) prostaglandin E2 (PGE2) production, thereby inhibiting the occurrence of human colon tumors. Furthermore, Guang et al¹⁷ revealed that *HIPK2* could inhibit P-catenin-mediated transcription, epidermal stem cell expansion, and skin tumors.

HIPK2 is the most studied member of the *HIPK* family of genes and is characterized by DNA damage response kinases that have both pro-apoptotic and anti-apoptotic functions to combat genotoxic and oxidative cell damage.^{18–22} Moreover, He et al²³ showed that *HIPK4* not only had less sequence homology with HIPKs 1, 2, and 3, but also had a high degree of sequence homology, suggesting that this kinase is highly conserved among species.

In 1998, Kim et al.⁶ first reported on *HIPK3* and that *HIPK3* mRNA is widely found in human and mammalian tissues. Northern blot analysis revealed that *HIPK3* is expressed as a ~7.5 kb tRNA, whereas in humans, *HIPK3* also contains an additional 4.4 kb transcript on chromosome seven. Young et al²⁴ labeled *HIPK3* protein with green fluorescent protein (GFP) and observed it in living cells. The GFP spots were




Figure 4 siR-HIPK3 enhanced the migration and invasion of A549 cells.

Notes: (A and B) A549 cell was transfected with siR-NC, siR-HIPK3, pcDNA-negative, or *HIPK3* overexpressed plasmid. At 48 hours after transfection, cell proliferation was measured by MTT assays; (C) number of invaded cells following *HIPK3* knockdown using specific siR-HIPK3 vs siR-NC as shown by staining with crystal violet. Bars indicate the invasion capability compared with that of siR-NC (\pm SD). Magnification $\times 200$. ** $P < 0.01$. (D) Representative images of wound healing were taken at 0 hour and 24 hours after the wound was scratched. Data are presented as mean \pm SD. Magnification $\times 100$. ** $P < 0.01$.

Abbreviations: NC, negative control; siR-HIPK3, siRNA-targeting *HIPK3*.

first observed in the nucleus and later in the cytoplasm, indicating that *HIPK3* protein is first present in the nucleus as a nuclear protein kinase. The *HIPK* protein family is highly phosphorylated during apoptosis, while purified *HIPK3* can phosphorylate NK domain homology transcription factor, suggesting that its family is a group of homologous domain-transforming phosphorylation kinases. Because NK cells are one of the major cells involved in FAS-mediated apoptosis, *HIPK3* is an important factor in FAS-mediated apoptosis and is a tumor suppressor gene. In our current study, as illustrated in Figure 1, both Western blotting and qRT-PCR showed a visible decrease in *HIPK3* expression levels in NSCLC tissues compared with that in the normal tissue. This result was consistent with the previous research results. Veronique et al²⁵ cloned full-length mouse and human *HIPK3* homology and found that 90% of the amino acid sequences were the same.

A gene study found that an intact *HIPK3* protein molecule was consisted of an NH₂-terminal kinase domain and a conserved PEST sequence, which had a COOH-terminus that could coincide with the FADD domain on FAS.

In 2004, Curtin et al²⁶ studied the role of *HIPK3* in the apoptotic prostate cancer cell line DU-145. When JNK inhibitor SP600125 was added to DU-145 and detected by Western blotting and flow cytometry, they found that as the JNK levels decreased, *HIPK3* and FAS-mediated apoptosis also decreased. After removing the JNK inhibitor, FAS-mediated apoptosis was significantly increased, *HIPK3* expression also increased, and there was a change in Caspase-3 expression levels. These results indicated that *HIPK3* was associated with FAS-mediated apoptosis. Moller²⁷ also reported *HIPK3* expression in the apoptotic human osteosarcoma cell line U20S; however, the clinical application of *HIPK3*, especially




Figure 5 siR-HIPK3 promoted the migration and invasion of HCC827 cells.

Notes: (A and D) MTT assays with siR-HIPK3 and HIPK3 overexpressed cells; (B and C) number of invaded cells following siR-HIPK3 vs siR-NC as shown by staining with crystal violet. Bars indicate the invasion capability compared with that of negative control (\pm SD). Magnification $\times 200$. $*P < 0.05$, $**P < 0.01$. (E and F) Migration of the HCC827 cells to the wound was visualized at 0 and 24 hours with inverted Leica phase contrast microscope ($\times 200$). $**P < 0.05$. Each time point was derived from three independent experiments.

Abbreviations: NC, negative control; siR-HIPK3, siRNA-targeting HIPK3.

the study of *HIPK3* in clinical NSCLC specimens, has not been reported.

In our current study, IHC results demonstrated that low *HIPK3* protein expression was significantly associated with pathology grade, TNM stage, lymph node metastasis, Ki-67 expression, and the 5-year survival rate of NSCLC patients. The multivariable analysis revealed that *HIPK3*, tumor size, TNM stage, Ki-67 expression, and age had independent prognostic effects on the overall survival of patients with NSCLC. Kaplan–Meier survival curves showed that NSCLC patients with higher *HIPK3* protein expression had a better prognosis. In addition, *HIPK3* knockdown using specific siRNA enhanced the migration and invasion of A549 and HCC827 cells. In vivo experiments in nude mice also demonstrated that *HIPK3* over-expression inhibited tumor

growth, whereas in contrast, *HIPK3*-shRNA promoted tumor growth in vivo.

Conclusion

Our findings confirmed that low expression of *HIPK3* in NSCLC tissues was significantly correlated with poor survival rates after curative resection. *HIPK3* could be used as a valuable biomarker for predicting the prognosis for NSCLC patients.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.




Figure 6 Necropsy images of mice with orthotopically implanted of A549 cells.

Notes: (A and B) Tumor volumes (mean±SD) in mice measured on the last day of the experiment. * $P < 0.05$ and # $P < 0.05$.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Acknowledgments

This study was supported by grants from Six Talent Peaks Project in Jiangsu Province (No WSN-059), the Science Foundation of Nantong City (No MS12015007), Scientific

Research Topic of Jiangsu provincial Health and Family Planning Commission (No H201626), and Key Talents of Medical Science in Jiangsu Province (No QNRC2016682).

Disclosure

The authors report no conflicts of interest in this work.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018, CA: a cancer journal for clinicians. 2018;68:7–30.

2. Ulahannan SV, Brahmer JR. Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. *Cancer Invest.* 2011;29(4):325–337.
3. Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: new biological insights and recent therapeutic advances. *CA Cancer J Clin.* 2011;61(2):91–112.
4. Tanoue LT, Tanner NT, Gould MK, Silvestri GA. Lung cancer screening. *Am J Respir Crit Care Med.* 2015;191(1):19–33.
5. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. *CA Cancer J Clin.* 2014;64(1):9–29.
6. Kim YH, Choi CY, Lee SJ, Conti MA, Kim Y. Homeodomain-interacting protein kinases, a novel family of co-repressors for homeodomain transcription factors. *J Biol Chem.* 1998;273(40):25875–25879.
7. Rinaldo C, Siepi F, Prodosmo A, Soddu S. HIPKs: Jack of all trades in basic nuclear activities. *Biochim Biophys Acta.* 2008;1783(11):2124–2129.
8. Chang WH, Liu TC, Yang WK, et al. Amiloride modulates alternative splicing in leukemic cells and resensitizes Bcr-AblT315I mutant cells to imatinib. *Cancer Res.* 2011;71(2):383–392.
9. van der Laden J, Soppa U, Becker W. Effect of tyrosine autophosphorylation on catalytic activity and subcellular localisation of homeodomain-interacting protein kinases (HIPK). *Cell Commun Signal.* 2015;13(3):3.
10. Akaïke Y, Kuwano Y, Nishida K, et al. Homeodomain-interacting protein kinase 2 regulates DNA damage response through interacting with heterochromatin protein 1 γ . *Oncogene.* 2015;34(26):3463–3473.
11. Rey C, Soubeyran I, Mahouche I, et al. HIPK1 drives p53 activation to limit colorectal cancer cell growth. *Cell cycle (Georgetown, Tex.).* 2013;12:1879–1891.
12. Li X, Zhang R, Luo D, et al. Tumor necrosis factor alpha-induced desumoylation and cytoplasmic translocation of homeodomain-interacting protein kinase 1 are critical for apoptosis signal-regulating kinase 1-JNK/p38 activation. *J Biol Chem.* 2005;280(15):15061–15070.
13. Ecsedy JA, Michaelson JS, Leder P. Homeodomain-interacting protein kinase 1 modulates Daxx localization, phosphorylation, and transcriptional activity. *Mol Cell Biol.* 2003;23(3):950–960.
14. Kondo S, Lu Y, Debbas M, et al. Characterization of cells and genotyped mice deficient for the p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1). *Proc Natl Acad Sci U S A.* 2003;100(9):5431–5436.
15. Nodale C, Sheffer M, Jacob-Hirsch J, et al. HIPK2 downregulates vimentin and inhibits breast cancer cell invasion. *Cancer Biol Ther.* 2012;13(4):198–205.
16. D’Orazi G, Sciulli MG, di Stefano V, et al. Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells. *Clin Cancer Res.* 2006;12(3 Pt 1):735–741.
17. Wei G, Ku S, Ma GK, et al. HIPK2 represses beta-catenin-mediated transcription, epidermal stem cell expansion, and skin tumorigenesis. *Proc Natl Acad Sci U S A.* 2007;104(32):13040–13045.
18. D’Orazi G, Cecchinelli B, Bruno T, et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. *Nat Cell Biol.* 2002;4(1):11–19.
19. Hofmann TG, Möller A, Sirma H, et al. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. *Nat Cell Biol.* 2002;4(1):1–10.
20. Zhang Q, Yoshimatsu Y, Hildebrand J, Frisch SM, Goodman RH. Homeodomain interacting protein kinase 2 promotes apoptosis by downregulating the transcriptional corepressor CtBP. *Cell.* 2003;115(2):177–186.
21. Zhang J, Pho V, Bonasera SJ, et al. Essential function of HIPK2 in TGFbeta-dependent survival of midbrain dopamine neurons. *Nat Neurosci.* 2007;10(1):77–86.
22. Hofmann TG, Glas C, Bitomsky N. HIPK2: A tumour suppressor that controls DNA damage-induced cell fate and cytokinesis, *BioEssays: news and reviews in molecular. Cellular and developmental biology.* 2013;35:55–64.
23. He Q, Shi J, Sun H, An J, Huang Y, Sheikh MS. Characterization of Human Homeodomain-interacting Protein Kinase 4 (HIPK4) as a Unique Member of the HIPK Family. *Molecular and Cellular Pharmacology.* 2010;2:61–68.
24. Higashimoto Y, Saito S, Tong XH, Hong A, Sakaguchi K, Appella E, Anderson CW. Human p53 is phosphorylated on serines 6 and 9 in response to DNA damage-inducing agents. *J Biol Chem.* 2000;275:23199–23203.
25. Venables JP, Bourgeois CF, Dalgliesh C, Kister L, Stevenin J, Elliott DJ. Up-regulation of the ubiquitous alternative splicing factor Tra2beta causes inclusion of a germ cell-specific exon. *Human molecular genetics.* 2005;14:2289–2303.
26. Curtin JF, Cotter TG. JNK regulates HIPK3 expression and promotes resistance to Fas-mediated apoptosis in DU 145 prostate carcinoma cells. *J Biol Chem.* 2004;279:17090–17100.
27. Moller A, Sirma H, Hofmann TG, et al. PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. *Cancer Res.* 2003;63:4310–4314.

OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on

Submit your manuscript here: <http://www.dovepress.com/oncotargets-and-therapy-journal>

patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress